Cargando…
Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report
Most hepatocellular carcinoma (HCC) patients have dismal prognoses because they are already in the advanced stage at the time of initial diagnosis and are unable to undergo upfront surgery. Recent studies of immune checkpoint inhibitors (ICIs) and antiangiogenic agents (AAAs) have shown encouraging...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670343/ https://www.ncbi.nlm.nih.gov/pubmed/34338239 http://dx.doi.org/10.1097/CAD.0000000000001163 |
_version_ | 1784614960450502656 |
---|---|
author | Fu, Lingli Chen, Ping Wang, Shijie Liu, Wenmin Chen, Zubing Chen, Hongbin Fu, Zhenming |
author_facet | Fu, Lingli Chen, Ping Wang, Shijie Liu, Wenmin Chen, Zubing Chen, Hongbin Fu, Zhenming |
author_sort | Fu, Lingli |
collection | PubMed |
description | Most hepatocellular carcinoma (HCC) patients have dismal prognoses because they are already in the advanced stage at the time of initial diagnosis and are unable to undergo upfront surgery. Recent studies of immune checkpoint inhibitors (ICIs) and antiangiogenic agents (AAAs) have shown encouraging results for unresectable HCC (uHCC). Here, we report a patient with uHCC who was treated with a combination of anlotinib and sintilimab (sintilimab 200 mg, intravenous glucose tolerance test, q21d and anlotinib 12 mg, orally, d1–14, q21d), an analog of the combination of lenvatinib and pembrolizumab with much lower cost. The patient with recurrent uHCC was downstaged to resectable disease by the combination therapy. After eight cycles of treatment with anlotinib and sintilimab, the patient underwent a second operation. The histology of the resected mass revealed a major and almost complete pathological response. However, this patient was diagnosed with type I diabetes mellitus with ketoacidosis after nearly 10 cycles of combination treatment with anlotinib and sintilimab. Active follow-ups revealed no signs of local recurrence or distant failure. In conclusion, this case report demonstrated that the combination of anlotinib and sintilimab, one of the strategies combining ICIs with AAAs, showed promising efficacy in the treatment of uHCC patients. |
format | Online Article Text |
id | pubmed-8670343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-86703432021-12-15 Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report Fu, Lingli Chen, Ping Wang, Shijie Liu, Wenmin Chen, Zubing Chen, Hongbin Fu, Zhenming Anticancer Drugs Case Reports Most hepatocellular carcinoma (HCC) patients have dismal prognoses because they are already in the advanced stage at the time of initial diagnosis and are unable to undergo upfront surgery. Recent studies of immune checkpoint inhibitors (ICIs) and antiangiogenic agents (AAAs) have shown encouraging results for unresectable HCC (uHCC). Here, we report a patient with uHCC who was treated with a combination of anlotinib and sintilimab (sintilimab 200 mg, intravenous glucose tolerance test, q21d and anlotinib 12 mg, orally, d1–14, q21d), an analog of the combination of lenvatinib and pembrolizumab with much lower cost. The patient with recurrent uHCC was downstaged to resectable disease by the combination therapy. After eight cycles of treatment with anlotinib and sintilimab, the patient underwent a second operation. The histology of the resected mass revealed a major and almost complete pathological response. However, this patient was diagnosed with type I diabetes mellitus with ketoacidosis after nearly 10 cycles of combination treatment with anlotinib and sintilimab. Active follow-ups revealed no signs of local recurrence or distant failure. In conclusion, this case report demonstrated that the combination of anlotinib and sintilimab, one of the strategies combining ICIs with AAAs, showed promising efficacy in the treatment of uHCC patients. Lippincott Williams & Wilkins 2021-07-30 2022-01 /pmc/articles/PMC8670343/ /pubmed/34338239 http://dx.doi.org/10.1097/CAD.0000000000001163 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Fu, Lingli Chen, Ping Wang, Shijie Liu, Wenmin Chen, Zubing Chen, Hongbin Fu, Zhenming Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
title | Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
title_full | Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
title_fullStr | Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
title_full_unstemmed | Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
title_short | Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
title_sort | complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670343/ https://www.ncbi.nlm.nih.gov/pubmed/34338239 http://dx.doi.org/10.1097/CAD.0000000000001163 |
work_keys_str_mv | AT fulingli completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport AT chenping completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport AT wangshijie completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport AT liuwenmin completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport AT chenzubing completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport AT chenhongbin completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport AT fuzhenming completepathologicalresponsewithdiabeticketoacidosistothecombinationofsintilimabandanlotinibinanunresectablehepatocellularcarcinomapatientacasereport |